Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA

APVO436 is a recombinant bispecific antibody designed to direct host cytotoxic T-cells to CD123-expressing blast cells in patients with hematologic malignancies. APVO436 showed promising tolerability and single-agent activity in relapsed or refractory (R/R) acute myeloid leukemia (AML) and myelodysp...

Descripció completa

Dades bibliogràfiques

Autors principals:	Justin Watts, Tara L. Lin, Alice Mims, Prapti Patel, Cynthia Lee, Anoush Shahidzadeh, Paul Shami, Elizabeth Cull, Christopher R. Cogle, Eunice Wang, Fatih M. Uckun
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2022-01-01
Col·lecció:	Frontiers in Oncology
Matèries:	AML – acute myeloid leukaemia CD123 expression venetoclax (BCL2 inhibitor) bispecific antibody (bsAb) myelodysplastic and myeloproliferative syndromes
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fonc.2021.806243/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!